fcγriib

Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E IgE)

Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor designed as a decoy or scavenger to target Fc and FcγR, binding and neutralizing pathogenic IgG. Its utility lies in mitigating autoimmune diseases, with a particular focus on systemic lupus erythematosus (SLE) research [1].

ADG-106 is a fully human agonistic monoclonal IgG4 antibody targeting CD137 (4-1BB). It activates CD137 through a potent FcγRIIB-mediated cross-linking mechanism while antagonizing the CD137 ligand. The isotype control for ADG-106 can be referred to as HumanIgG4(S228P) kappa, Isotype Control.

MGD010 is a bispecific antibody targeting CD32B (FcγRIIb) and CD79B. By simultaneously co-engaging CD32B (FcγRIIb) and the BCR component CD79B, MGD010 delivers an inhibitory signal, thereby suppressing activated B cells. MGD010 shows potential for research in autoimmune diseases.

BI-1206 is a recombinant antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). It inhibits CD20 internalization induced by Rituximab, whether used alone or in combination with drugs such as Ibrutinib, Venetoclax, and CHOP. BI-1206 can enhance or restore the activity of Rituximab or other anti-CD20 monoclonal antibodies and demonstrates cytolytic activity against malignant B cells. BI-1206 is applicable in research on cancers such as mantle cell lymphoma (MCL).